3,6-dihydroxy-24-amidyl steroid derivatives

A pharmaceutical composition for treating a UR- or a LXR-mediated disorder, said composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound of the following formula:

• wherein
• each of R1, R2, R4, R4′, R5, R7, R8, R9, R11, R12, R14, R15, R16, and R17′, independently, is hydrogen;
• each of R3 and R6, independently, is hydroxy;
• each of R10 and R13, independently, is alkyl, haloalkyl, or hydroxyalkyl;
• R17 is —X—Y—Z, in which
• X is alkyl or alkenyl;
• Y is —CO—NH— or —CO—N(alkyl)-;
• and
• Z is alkynyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, heteroaryl, or heteroaralkyl, and is optionally substituted with hydroxy, alkoxy, halo, oxo, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, or alkylthio;
• is straight chain C1-C8 alkyl, alkenyl, or cycloalkyl, which is substituted with hydroxy, alkoxy, halo, oxo, alkylcarbonyloxy, alkylaminocarbonyl, alkylcarbonylamino, alkylcarbonyl, alkylsulfinyl, or alkylthio;
• or is —CH(A)—B with A being an amino acid side chain containing an aromatic moiety, and B being hydrogen, —NRaRb, or —COORc wherein each of Ra, Rb, and Rc, independently, is hydrogen or alkyl;
• and
• n is 0;
• or a salt thereof.